FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Active, not recruiting · NCT06332092 · Registry updated 2026-03-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-03-16 | NCT06332092 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fulgent Pharma LLC. | 2 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | United States | 22 |
| Highlands Oncology - North Hills | Fayetteville | United States | 1 |
| Moffitt Cancer Center Magnolia Campus | Tampa | United States | 3 |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | United States | 19 |
| Texas Oncology - Northeast Texas Cancer & Research Institute | Tyler | United States | 1 |
| USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles | United States | 2 |